Mastodawn

ScienceOpen Aug 22, 2025

Covering the latest in #Gastroenterology — from causes and mechanisms to therapy, clinical research, and case reports.

Explore the #KargerPublishers collection on #ScienceOpen 🔬📚👇

🔗 https://www.scienceopen.com/collection/Karger_Gastroenterology

Karger: Gastroenterology

Karger Gastroenterology covers a wide spectrum. Our international journal of gastroenterology focusing on clinical research reports is <a href="https://www.karger.com/Journal/Home/223838">Digestion</a>, whereas <a href="https://www.karger.com/Journal/Home/224231">Digestive Diseases</a> deals with the latest in diagnosis and treatment of gastrointestinal disorders.

ScienceOpen

ScienceOpen Aug 22, 2025

📄 'Treatment of Plaque Psoriasis with Guselkumab Reduces Systemic Inflammatory Burden as Measured by Neutrophil/Lymphocyte Ratio, Platelet/Lymphocyte Ratio, and Monocyte/Lymphocyte Ratio: A post hoc Analysis of Three Randomised Clinical Trials' - an article in the #KargerPublishers research collection on #ScienceOpen:

🔎🔗 https://www.scienceopen.com/document?vid=ac8b97db-bc83-4f86-ad4b-32df11bfa6d3

#PlaquePsoriasis #Guselkumab #SystemicInflammation #CardioDerm #IL23Inhibitor #CardiovascularRisk

Treatment of Plaque Psoriasis with Guselkumab Reduces Systemic Inflammatory Burden as Measured by Neutrophil/Lymphocyte Ratio, Platelet/Lymphocyte Ratio, and Monocyte/Lymphocyte Ratio: A post hoc Analysis of Three Randomised Clinical Trials

Introduction: Psoriasis is associated with an increased risk of cardiovascular disease (CVD). Previous studies have found that treatment with tumour necrosis factor or interleukin (IL)-17 inhibitors leads to reductions in the systemic inflammation biomarkers neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and monocyte/lymphocyte ratio (MLR). The primary aim of this study was to evaluate changes in NLR, PLR and MLR with guselkumab compared with placebo (VOYAGE I/II), adalimumab (VOYAGE I/II), and secukinumab (ECLIPSE). The secondary aims were to assess correlation with disease severity, C-reactive protein (CRP) levels, and treatment response. Methods: This was a post hoc analysis of VOYAGE I, VOYAGE II, and ECLIPSE Phase III randomised trial data on guselkumab for moderate-to-severe plaque psoriasis. NLR, PLR, and MLR were evaluated at baseline and Week 16 in VOYAGE I and II and at baseline and Week 12 in ECLIPSE. Mean changes were compared between groups using a Student’s t test; Pearson’s test was used for correlation analyses. Results: VOYAGE I included 837 randomised patients, VOYAGE II included 992 randomised patients, and ECLIPSE included 1,048 randomised patients. In VOYAGE I, NLR ( p = 0.011), PLR ( p = 0.015), and MLR ( p = 0.004) decreased significantly following 16 weeks of guselkumab treatment vs. placebo. In VOYAGE II, reductions in NLR ( p = 0.003), PLR ( p = 0.006), and MLR ( p = 0.001) were greater at Week 16 in patients treated with guselkumab vs. placebo. Treatment with adalimumab was associated with a greater reduction ( p < 0.001) in the three biomarkers vs. guselkumab, while secukinumab resulted in a similar reduction in NLR, PLR, and MLR compared with guselkumab ( p = 0.413, 0.650, and 0.498, respectively). All biomarkers weakly correlated with Psoriasis Area and Severity Index (PASI) at baseline and showed modest correlations with CRP levels. Biomarkers in patients who were PASI90 responders were consistent between all active treatment groups at baseline. Conclusions: Guselkumab is a highly efficacious treatment for plaque psoriasis; the study has demonstrated the potential benefit of treatment with guselkumab in reducing systemic inflammation as measured by NLR, PLR, and MLR, which appeared to be independent of psoriasis response, suggesting that reducing systemic inflammation with guselkumab may decrease CVD risk.

ScienceOpen

ScienceOpen Aug 22, 2025

📄 'Process Evaluation of an Ambulance-Delivered Early Intensive Blood Pressure-Lowering Stroke Trial: Design, Rationale, and Reflection' - an article in the #KargerPublishers research collection on #ScienceOpen:

🔎🔗 https://www.scienceopen.com/document?vid=e9ada19d-30c1-4bdd-bf72-74bfccaf1246

#AcuteStroke #INTERACT4 #PrehospitalCare #ImplementationScience #BloodPressureControl

Process Evaluation of an Ambulance-Delivered Early Intensive Blood Pressure-Lowering Stroke Trial: Design, Rationale, and Reflection

Introduction: The fourth INTEnsive ambulance-delivered blood pressure Reduction in hyper-ACute stroke Trial (INTERACT4) is a large-scale, multicenter, prospective, randomized, open-label, blinded endpoint assessment trial, initiated in an ambulance in China, aiming at evaluating the effectiveness and safety of prehospital blood pressure (BP) lowering in patients with suspected acute stroke and elevated BP. A prespecified process evaluation is intended to explore the implementation of the trial intervention, provide support to interpret the trial outcomes and put forward suggestions to scale up the intervention in broader settings in the future. Methods: This process evaluation is a mixed-methods design, and follows the Normalization Process Theory (NPT) and the UK Medical Research Council (UK MRC) guidance. Fidelity, reach, acceptability, appropriateness, adoption, sustainability, and relevant contextual factors and mechanisms affecting the implementation of prehospital early intensive BP-lowering treatment will be analyzed. Semi-structured interviews with ambulance staff, ward and emergency department clinicians, and nurses are undertaken to explore perceptions of the intervention, contextual factors, and potential suggestions for future implementation in practice. Data from observational records, surveys, conventional monitoring data, on-site records, and case report forms will be analyzed to understand background care and context. Conclusion: The process evaluation of INTERACT4 will provide insights for the implementation of prehospital early intensive BP-lowering intervention in different health systems and help better explain the trial results for further scale up.

ScienceOpen

ScienceOpen Aug 21, 2025

🌐🔬 Connecting people and science through high-quality publications and services that make knowledge accessible, visible, and applicable.

Discover the #KargerPublishers portfolio of curated research collections across the #HealthSciences via #ScienceOpen. 📚🩺

🔗 https://www.scienceopen.com/collection/KargerPublishers

Karger Publishers

Karger Super Collection

ScienceOpen

Fran Mar 15, 2024

💥A founder, a Librarian, a Chef and a Science Communicator enter a pub.
Not a joke, just the new FREE Karger in Conversation online event: Is Open Access Truly Open to All?
We've put together a stellar panel:
- Dr Roger Schonfeld, Ithaka S+R
- Dr Beth Montague-Hellen,The Francis Crick Institute.
- Dr. Sarah Wettstadt, SciComm Society
- Hannah Hope Open Research, Wellcome Trust.
Register ➡️https://register.gotowebinar.com/register/434112916197249120
#Research #OpenAccess #ScholarlyPublishing #SciComms #KargerPublishers #SciComm #OA

Fran Feb 28, 2024

STARTING NOW!💥We are pleased to invite you to join our free webinar!
"Impact Beyond Academia: Advancing Science Communication After Publication"

Wednesday 28th February 2024 – 3.30-4.30 PM CET time

👉 REGISTER HERE (to watch now or to get a recording!)

https://lnkd.in/dQAkcydP

Learn the art of sharing your research with the world!

(Given the time difference for some of you, there will be a recording that will be available for those that register for the webinar.)
#KargerPublishers #SciComm

LinkedIn

This link will take you to a page that’s not on LinkedIn

Fran Sep 19, 2023

Register to our FREE Panel discussion on the Future of OA in Scholarly publishing! By registering you will also get the recording if you're not able to attend on the 20th September (3PM) https://tinyurl.com/KargerOAPanel #KargerPublishers #OpenAccess #OA #webinar